A previous study with 93 cases showed that a high pretherapeutic CD8+/FOXP3+ intraepithelial lymphocyte ratio was associated with favorable tumor regression [13], which is consistent with our finding of a specific association between the density of CD8+ TIL and the treatment response. The gene discussed is FOXP3; the disease is neoplasm.